Table 2. Proportion BKPyV viremia.

	6 weeks (p = 0.45)		3 month (p = 0.68)		6 month (p = 0.02)		12 month (p = 0.015)		24 month (p = 0.08)
	CsAM n = 41	TacM n = 30	CsAM n = 41	TacM n = 31	CsAM n = 37	TacM n = 29	CsAM n = 34	TacM n = 32	CsAM n = 23	TacM n = 24
0–2 log10 cp/ml, n (%)	33 (80.5)	27 (90.0)	18 (43.9)	17 (54.8)	19 (51.4)	11 (37.9)	25 (73.5)	17 (53.1)	19 (82.6)	14 (58.3)
2–3 log10 cp/ml, n (%)	5 (12.2)	1 (3.3)	5 (12.2)	3 (9.7)	10 (27.0)	3 (10.3)	7 (20.6)	3 (9.4)	4 (17.4)	4 (16.7)
3–4 log10 cp/ml, n (%)	2 (4.9)	2 (6.7)	11 (26.8)	5 (16.1)	5 (13.5)	4 (13.8)	1 (2.9)	3 (9.4)	0 (0.0)	4 (16.7)
>4 log10 cp/ml, n (%)	1 (2.4)	0 (0.0)	7 (17.1)	6 (19.4)	3 (8.1)	11 (37.9)	1 (2.9)	9 (28.1)	0 (0.0)	2 (8.3)

Chi squared test was used for the proportion of BKPyV viremia at the different time points between the CsA and Tac treatment group.